Precision BioSciences, Inc. (DTIL)
Stock Price:
$6.98 USD
0.13 (1.90%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
365.37M |
| Revenue (ttm) |
19.46M |
| Net Income (ttm) |
-101.20M |
| Shares Out |
52.34M |
| EPS (ttm) |
-1.98 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$6.98 |
| Previous Close |
$6.85 |
| Change ($) |
0.13 |
| Change (%) |
1.90% |
| Day's Open |
6.89 |
| Day's Range |
6.72 - 7.00 |
| Day's Volume |
314,838 |
| 52-Week Range |
4.46 - 23.67 |
More Stats
| Market Cap |
365.37M |
| Enterprise Value |
249.40M |
| Earnings Date (est) |
Nov 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
52.34M |
| Float |
38.47M |
| EPS (basic) |
-1.92 |
| EPS (diluted) |
-1.98 |
| FCF / Share |
-1.94 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.81M |
| Short Ratio |
3.24 |
| Short % of Float |
7.30% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
18.77 |
| PB Ratio |
4.27 |
| Revenue |
19.46M |
| Operating Income |
-104.14M |
| Net Income |
-101.20M |
| Free Cash Flow |
-100.58M |
| Net Cash |
115.97M |
| Net Cash / Share |
2.22 |
| Gross Margin |
114.26% |
| Operating Margin |
-535.08% |
| Profit Margin |
-519.90% |
| FCF Margin |
-516.77% |
| ROA |
-28.54% |
| ROE |
-77.97% |
| ROIC |
-303.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
7 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$17.57*
(151.72% upside)
Low
6.00
Current: $6.98
High
25.00
Target: 17.57
*Average 12-month price target from 7 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | 22.24 | 10.88 | 6.48 |
| Revenue Growth | 104.34% | 67.84% | - |
| Gross Profit | 22.24 | 10.88 | 6.48 |
| Operating Income | -87.20 | -47.91 | -21.97 |
| Net Income | -92.88 | -46.04 | -21.10 |
| Shares Outstanding | 41.99 | 15.78 | 15.91 |
| Earnings Per Share | -2.21 | -2.92 | -1.33 |
| Operating Cash Flow | -71.02 | -51.72 | -24.17 |
| Capital Expenditures | -24.67 | -15.66 | -5.52 |
| Free Cash Flow | -95.68 | -67.39 | -29.68 |
| Cash & Equivalents | 181 | 103 | 62.80 |
| Net Cash / Debt | 181 | 103 | 62.80 |
| Assets | 235 | 139 | 72.68 |
| Liabilities | 96.92 | 98.64 | 99.05 |
| Book Value | 138 | 39.96 | -26.37 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Precision BioSciences, Inc. |
| Country |
United States |
| Employees |
220 |
| CEO |
Matthew R. Kane |
Stock Information
| Ticker Symbol |
DTIL |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: DTIL |
| IPO Date |
March 28, 2019 |
Description
Precision BioSciences operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and PBCAR20AL, an allogeneic anti-CD20 CAR T for the treatment NHL, chronic lymphocytic leukemia, and small lymphocytic lymphoma. The Food segment develops food and nutrition products. The company has development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.